This Is MS Multiple Sclerosis Knowledge & Support Community

Fatigue is a significant symptom in multiple sclerosis (MS) patients. First-generation disease modifying therapies (DMTs) are at best moderately effective to improve fatigue.

Observations from small cohorts have indicated that natalizumab, an antibody targeting VLA-4, may reduce MS-related fatigue. The TYNERGY study aimed to further evaluate the effects of natalizumab treatment on MS-related fatigue...... Read More - http://www.ms-uk.org/index.cfm/tysabri

Can you imagine what the comments would be by the established MS world of medicine if someone outside of this group did a one-armed, non-controlled study of their drug and used the words "might" or "may" reduce fatigue to describe the results?!